NEW YORK, Oct. 20, 2015 /PRNewswire/ -- Influenza vaccines are considered as an optimum source of prevention from diseases caused by flu virus. Since the H1N1 pandemic, worldwide authorities have started to adopt proactive approach in the vaccination process. Virus of previous pandemics are still circulating in the environment and in the coming future, they may be classified as strains to be updated in seasonal vaccines. Moreover, a large chunk of global population is affected by influenza-related problems. In such a scenario, huge opportunity lies for industry participants to tap the fast growing market.
In 2014, the global market for influenza vaccines has shown tremendous growth backed by certain key prominent factors. Approval of new seasonal influenza vaccines by authorities and significant developments in adjuvant technology are going to impact the market in a positive manner. The global volume sales of influenza vaccine is expected to grow at a CAGR of 5.5% during the forecasted period, i.e., 2014-2020.
Emerging markets predominantly is the main focus in the global influenza vaccine market landscape. Vast population base together with significantly low vaccination coverage are the prominent factors that will drive the future growth in countries, such as China and India. Market players have already started devising strategies including agreements with domestic manufacturers/distributors to increase their presence in China. India, on the contrary, is engaged in the collection of data that may facilitate in the development of flu vaccination strategies among the population.
In our report "Global Influenza Vaccine Market Outlook 2020", we have segmented the global influenza vaccine market based on the major vaccine in the market and volume and value sales for each vaccine have been analyzed. Followed by this, important geographies have been highlighted along with their current and future markets outlook till 2020. The report also covers advanced stage pipeline analysis of key players, which list down the influenza vaccines already in Phase III trials.
In the end, various key players have been enlisted. Our team has analyzed each company's financial performance along with its vaccine portfolio and pipeline that will help the reader to better position his company vis-à-vis competition.
Read the full report: http://www.reportlinker.com/p02861482-summary/view-report.html
ReportLinker is an award-winning market research solution. Reportlinker reviews, finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
Contact Clare: [email protected]
Intl: +1 339-368-6001